CRISPR-Cas9 Fundamental Uses: Analysis of Human Genome Engineering Through CRISPR/Cas9
- DOI
- 10.2991/978-2-494069-31-2_289How to use a DOI?
- Keywords
- CRISPR/Cas9; gene editing; therapeutics; guide RNA; bioethics
- Abstract
The invention of CRISPR-Cas9 allowed the wanted genome to be targeted and edited. Clustered regularly interspaced short palindromic repeats (CRISPR) combined with Cas9 protein together can be diverted to a guided location in the genome, editing the DNA strand. This achievement improved the human body’s genomes and turned them into cells. CRISPR-Cas9 could be used in cells and animal model generations, and it has been proven that human embryos can be similarly modified. The passage analysis has also included the type II bacterial CRISPR system with custom guide RNA (gRNA) in human cells, which allowed the team to implement sophisticated investigations and experiments: endogenous AAVS1 locus in targeting T cells, K562 cells, and induced pluripotent stem cells. The experiment research provides guidelines for the future development target sites, cleavage efficiency, and off-target activity analysis.
- Copyright
- © 2022 The Author(s)
- Open Access
- Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
Cite this article
TY - CONF AU - Yushun Tian PY - 2022 DA - 2022/12/29 TI - CRISPR-Cas9 Fundamental Uses: Analysis of Human Genome Engineering Through CRISPR/Cas9 BT - Proceedings of the 2022 6th International Seminar on Education, Management and Social Sciences (ISEMSS 2022) PB - Atlantis Press SP - 2464 EP - 2473 SN - 2352-5398 UR - https://doi.org/10.2991/978-2-494069-31-2_289 DO - 10.2991/978-2-494069-31-2_289 ID - Tian2022 ER -